• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by LumiraDx Limited

    2/6/24 4:34:15 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $LMDX alert in real time by email
    6-K 1 copy_of_form_6-k_liquida.htm 6-K 6-K

     


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 6-K

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of February 2024.

    Commission File Number: 001-40852


    LUMIRADX LIMITED

    (In Official Liquidation)

     

    (Translation of registrant's name into English)

    LumiraDx Limited
    c/o Ocorian Trust (Cayman) Limited
    PO Box 1350, Windward 3, Regatta Office Park
    Grand Cayman KY1-1108

    Cayman Islands

    (354) 640-0540
    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    Form 20-F ☒ Form 40-F ☐

     

     


     

    NOTICE OF APPOINTMENT OF JOINT OFFICIAL LIQUIDATORS

     

    LumiraDx Limited (In Official Liquidation)

     

    On February 1, 2024, the Grand Court of the Cayman Islands (the “Cayman Court”) ordered that LumiraDx Limited (the “Company”) be wound up in accordance with the Cayman Islands' Companies Act (As Revised) and that Margot MacInnis and Sandipan Bhowmik of Grant Thornton Specialist Services (Cayman) Limited, 2nd Floor, Century Yard, Cricket Square, PO Box 1044, Grand Cayman KY1-1102, Cayman Islands, be appointed as joint official liquidators of the Company (the “Joint Official Liquidators”).

    As a result of the appointment of the Joint Official Liquidators, the directors are no longer in control of the Company’s affairs and are no longer responsible for the management of the Company’s business.

    As previously announced, trading of the Company’s securities was suspended by The Nasdaq Stock Market LLC on January 9, 2024. Following the appointment of the Joint Official Liquidators, pursuant to section 99 of the Cayman Islands' Companies Act (As Revised), transfers (including acquisitions and disposals) of the shares in the Company will only be effective if validated by the Cayman Court. Consequently, by virtue of the Joint Official Liquidators’ appointment, no transfer of the Company’s shares from February 1, 2024 onward will be effective unless subsequently validated by the Cayman Court.

    The Joint Official Liquidators have determined that the Company should be treated as insolvent for the purposes of \Orders 8 and 9 of the Cayman Islands' Companies Winding Up Rules (As Revised). The Joint Official Liquidators may change their determination in light of changes of relevant circumstances and/or their assessment of the Company’s financial position, however it is currently anticipated that there will be insufficient realisations in the liquidation to repay creditors in full. In any event, the shareholders of the Company will rank behind creditors in the statutory priority of payments in the event that distributable assets are recovered and therefore no return is expected to shareholders of the Company.

    Any stakeholders wishing to contact the Joint Official Liquidators are invited to do so via the following correspondence address which will be regularly monitored: [email protected]

     


     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

     

    LUMIRADX LIMITED

    Date: February 6, 2024

     

     

     

    By:

    /s/ Sandipan Bhowmik

     

    Name:

    Sandipan Bhowmik

     

    Title:

    Joint Official Liquidator

     

     


    Get the next $LMDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LMDX

    DatePrice TargetRatingAnalyst
    3/11/2022$13.00 → $9.00Outperform
    Raymond James
    11/15/2021$20.00Outperform
    Evercore ISI Group
    10/27/2021$12.00Buy
    BTIG Research
    10/25/2021$13.00Outperform
    Raymond James
    More analyst ratings

    $LMDX
    SEC Filings

    See more
    • SEC Form 6-K filed by LumiraDx Limited

      6-K - LumiraDx Ltd (0001685428) (Filer)

      2/6/24 4:34:15 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 6-K filed by LumiraDx Limited

      6-K - LumiraDx Ltd (0001685428) (Filer)

      12/29/23 4:26:15 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 6-K filed by LumiraDx Limited

      6-K - LumiraDx Ltd (0001685428) (Filer)

      12/8/23 7:15:38 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LMDX
    Leadership Updates

    Live Leadership Updates

    See more
    • LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th

      LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX)(the "Company") today announced that it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") that its securities will be suspended from trading at the open of business on January 9, 2024 as a result of the Company's failure to maintain compliance with Nasdaq's continued listing standards. As previously disclosed, on October 24, 2023, the Company received a notice from Nasdaq's Listing Qualifications Department (the "Staff") stating that the Company's securities were subject to delisting from The Nasdaq Global Market due to a failure to maintain compliance with the minimum bid price requirement of Nasd

      1/5/24 5:45:23 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche

      LONDON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX) (the "Company"), a next generation point of care diagnostics company, announced today the appointment of joint administrators for two of its subsidiaries. The administrators have signed a definitive agreement to sell certain companies of the LumiraDx group related to LumiraDx's innovative point of care technology to Roche. The Company announced today that Andrew Johnson, Lisa Rickelton and Lindsay Hallam of FTI Consulting LLP have been appointed as joint administrators of two of its subsidiaries, LumiraDx Group Limited and LumiraDx International Limited, which together hold substantially all of the assets of the Lumi

      12/29/23 4:15:50 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LMDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th

      LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX)(the "Company") today announced that it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") that its securities will be suspended from trading at the open of business on January 9, 2024 as a result of the Company's failure to maintain compliance with Nasdaq's continued listing standards. As previously disclosed, on October 24, 2023, the Company received a notice from Nasdaq's Listing Qualifications Department (the "Staff") stating that the Company's securities were subject to delisting from The Nasdaq Global Market due to a failure to maintain compliance with the minimum bid price requirement of Nasd

      1/5/24 5:45:23 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche

      LONDON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX) (the "Company"), a next generation point of care diagnostics company, announced today the appointment of joint administrators for two of its subsidiaries. The administrators have signed a definitive agreement to sell certain companies of the LumiraDx group related to LumiraDx's innovative point of care technology to Roche. The Company announced today that Andrew Johnson, Lisa Rickelton and Lindsay Hallam of FTI Consulting LLP have been appointed as joint administrators of two of its subsidiaries, LumiraDx Group Limited and LumiraDx International Limited, which together hold substantially all of the assets of the Lumi

      12/29/23 4:15:50 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal

      LONDON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- On October 24, 2023, LumiraDx Limited (NASDAQ:LMDX)(the "Company") received a notice ("Notice") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") stating that on April 21, 2023, the Staff had notified the Company that the bid price of its listed securities had closed at less than $US1.00 per share over the previous 30 consecutive business days, and, as a result, did not comply with Listing Rule 5450(a)(1) (the "Minimum Bid Requirement"). Therefore, in accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until October 18, 2023, to regain compliance with the Minimu

      10/27/23 4:45:02 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LMDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James reiterated coverage on LumiraDx with a new price target

      Raymond James reiterated coverage of LumiraDx with a rating of Outperform and set a new price target of $9.00 from $13.00 previously

      3/11/22 7:22:18 AM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Evercore ISI Group initiated coverage on LumiraDx with a new price target

      Evercore ISI Group initiated coverage of LumiraDx with a rating of Outperform and set a new price target of $20.00

      11/15/21 8:56:20 AM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • BTIG Research initiated coverage on LumiraDx with a new price target

      BTIG Research initiated coverage of LumiraDx with a rating of Buy and set a new price target of $12.00

      10/27/21 8:35:45 AM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LMDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)

      SC 13G/A - LumiraDx Ltd (0001685428) (Subject)

      2/12/24 4:06:57 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)

      SC 13G/A - LumiraDx Ltd (0001685428) (Subject)

      2/9/24 4:16:20 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13D/A filed by LumiraDx Limited (Amendment)

      SC 13D/A - LumiraDx Ltd (0001685428) (Subject)

      12/29/23 1:52:49 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LMDX
    Financials

    Live finance-specific insights

    See more
    • LumiraDx Reports Second Quarter 2023 Results

      LONDON, Aug. 24, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its second quarter ended June 30, 2023. Second quarter 2023 revenues of $21.0 millionSubmitted First 510(k) Application to the U.S. Food and Drug Administration (FDA) for 5-minute COVID Ultra testSubmitted COVID/Flu combo test for FDA Emergency Use Authorization (EUA) as part of the NIH's Independent Test Assessment (ITAP) programMore than 1,500 new instruments shipped in Q2, primarily to U.S. pharmacy locations to expand testing capacity for the upcoming respiratory season Ron Zwanziger, Chairman and CEO of LumiraD

      8/24/23 7:45:00 AM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24

      LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited  (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 24, 2023. On the day of the release, LumiraDx will host a conference call and webcast at 8:30 AM Eastern Time to review the financial results and business highlights.    LumiraDx Second Quarter 2023 Financial Results Conference Call  Date:Thursday, August 24, 2023Time:8:30 AM Eastern Time   Live Call/Webcast:   Register to join by phone here.  View webcast: https://investors.lumiradx.com/news-and-events/investor-calendar    A replay of the webcast will be available on the Inv

      8/16/23 4:30:00 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • LumiraDx Reports First Quarter 2023 Results

      LONDON, May 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its first quarter ended March 31, 2023. First quarter 2023 revenues of $22.2 million.Cost reduction programs implemented across the global organization resulting in declining operating losses.US Clinical Studies for first 510K submission completed.More than 100 customers in the first full launch quarter for the world's first quantitative finger stick NT-proBNP assay. Ron Zwanziger, Chairman and CEO of LumiraDx, stated, "Our transition to non-COVID is beginning to develop, especially with the commercial launches of HbA1c

      5/16/23 7:45:00 AM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care